Article Details
Retrieved on: 2025-04-14 16:05:30
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses AB Science's patent for masitinib, a drug targeting severe sickle cell disease (SCD), which presents a significant public health challenge in Africa. Masitinib, offering a new approach to managing SCD complications, aligns with existing treatments like hydroxycarbamide and potential gene therapy.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here